Lauren D Liao, Emilie Højbjerre-Frandsen, Alan E Hubbard, Alejandro Schuler
{"title":"Prognostic adjustment with efficient estimators to unbiasedly leverage historical data in randomized trials.","authors":"Lauren D Liao, Emilie Højbjerre-Frandsen, Alan E Hubbard, Alejandro Schuler","doi":"10.1515/ijb-2024-0018","DOIUrl":null,"url":null,"abstract":"<p><p>Although randomized controlled trials (RCTs) are a cornerstone of comparative effectiveness, they typically have much smaller sample size than observational studies due to financial and ethical considerations. Therefore there is interest in using plentiful historical data (either observational data or prior trials) to reduce trial sizes. Previous estimators developed for this purpose rely on unrealistic assumptions, without which the added data can bias the treatment effect estimate. Recent work proposed an alternative method (prognostic covariate adjustment) that imposes no additional assumptions and increases efficiency in trial analyses. The idea is to use historical data to learn a prognostic model: a regression of the outcome onto the covariates. The predictions from this model, generated from the RCT subjects' baseline variables, are then used as a covariate in a linear regression analysis of the trial data. In this work, we extend prognostic adjustment to trial analyses with nonparametric efficient estimators, which are more powerful than linear regression. We provide theory that explains why prognostic adjustment improves small-sample point estimation and inference without any possibility of bias. Simulations corroborate the theory: efficient estimators using prognostic adjustment compared to without provides greater power (i.e., smaller standard errors) when the trial is small. Population shifts between historical and trial data attenuate benefits but do not introduce bias. We showcase our estimator using clinical trial data provided by Novo Nordisk A/S that evaluates insulin therapy for individuals with type 2 diabetes.</p>","PeriodicalId":50333,"journal":{"name":"International Journal of Biostatistics","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biostatistics","FirstCategoryId":"100","ListUrlMain":"https://doi.org/10.1515/ijb-2024-0018","RegionNum":4,"RegionCategory":"数学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Although randomized controlled trials (RCTs) are a cornerstone of comparative effectiveness, they typically have much smaller sample size than observational studies due to financial and ethical considerations. Therefore there is interest in using plentiful historical data (either observational data or prior trials) to reduce trial sizes. Previous estimators developed for this purpose rely on unrealistic assumptions, without which the added data can bias the treatment effect estimate. Recent work proposed an alternative method (prognostic covariate adjustment) that imposes no additional assumptions and increases efficiency in trial analyses. The idea is to use historical data to learn a prognostic model: a regression of the outcome onto the covariates. The predictions from this model, generated from the RCT subjects' baseline variables, are then used as a covariate in a linear regression analysis of the trial data. In this work, we extend prognostic adjustment to trial analyses with nonparametric efficient estimators, which are more powerful than linear regression. We provide theory that explains why prognostic adjustment improves small-sample point estimation and inference without any possibility of bias. Simulations corroborate the theory: efficient estimators using prognostic adjustment compared to without provides greater power (i.e., smaller standard errors) when the trial is small. Population shifts between historical and trial data attenuate benefits but do not introduce bias. We showcase our estimator using clinical trial data provided by Novo Nordisk A/S that evaluates insulin therapy for individuals with type 2 diabetes.
期刊介绍:
The International Journal of Biostatistics (IJB) seeks to publish new biostatistical models and methods, new statistical theory, as well as original applications of statistical methods, for important practical problems arising from the biological, medical, public health, and agricultural sciences with an emphasis on semiparametric methods. Given many alternatives to publish exist within biostatistics, IJB offers a place to publish for research in biostatistics focusing on modern methods, often based on machine-learning and other data-adaptive methodologies, as well as providing a unique reading experience that compels the author to be explicit about the statistical inference problem addressed by the paper. IJB is intended that the journal cover the entire range of biostatistics, from theoretical advances to relevant and sensible translations of a practical problem into a statistical framework. Electronic publication also allows for data and software code to be appended, and opens the door for reproducible research allowing readers to easily replicate analyses described in a paper. Both original research and review articles will be warmly received, as will articles applying sound statistical methods to practical problems.